The stock's fall snapped a three-day winning streak.

Maxim Group analyst Michael Okunewitch maintained a Hold rating on Gilead Sciences (GILD – Research Report) today. The company’s shares closed ...

Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report)’s share price reached a new 52-week high during mid-day trading on Wednesday following a better than expected earnings announcement. The company ...

Andrew Dickinson, the Chief Financial Officer of Gilead Sciences, Inc. (NASDAQ:GILD), recently executed a series of transactions involving the company's stock. On February 12, Dickinson sold 137,676 ...

This week's dividend activity included increased payouts from Gilead Sciences (GILD) and Meta Platforms (NASDAQ:META) as well as declarations from companies such as Nike (NYSE:NKE) and Unilever (UL).

The company, helmed by BioNTech alums, is developing therapies aimed at dermatological, respiratory and gut-related ...

The Chargers hosted the Palisades High School football program at The Bolt. Upon arrival, the Pali High student-athletes all received Chargers practice gear and headed to the weight room for an ...

A patent dispute between ViiV Healthcare and Gilead Sciences has been resolved, with Gilead agreeing to pay a $1.25 billion settlement as well as royalties on sales of one of its top HIV products.

It is vital for sponsors to reduce the burden on the site if they also want to lessen the strain on patients, said Shantheri Pai, associate director clinical operations for oncology at Gilead while ...

There exists no ‘amyloid cabal’” in Alzheimer’s research, neurologist Dennis Selkoe writes in response to Charles Piller’s “Doctored.” ...